Although a direct metabolite mediating these effects was not identified, it is important to recall IL6 involvement in obesity-associated inflammation (60) and recent findings where IL6 signaling was reported to render resistance to ICB therapy (172). Here, IL6 is linked to obesity due to melanocortin 4 receptor deficiency.